Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies

Hideaki Kodama, Masanori Suzuki, Yu Katayose, Masao Shinoda, Naoki Sakurai, Shin Ichi Takemura, Hiroshi Yoshida, Hisaaki Saeki, Ryutaro Asano, Masahiko Ichiyama, Kohzoh Imai, Yuji Hinoda, Seiki Matsuno, Toshio Kudo

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


For the purpose of establishing a new adoptive immunotherapy for bile duct carcinoma (BDC), we previously constructed two kinds of bispecific antibodies (bsAbs), anti-MUC1 × anti-CD3 (M × 3) and anti-MUC1 × anti-CD28 (M × 28), which activate T cells and form bridges between them and MUC1-expressing tumor cells. In our previous studies [Cancer Res. 56 (1996) 4205] specific targeting therapy (STT) consisting of i.v. administration of lymphokine activated killer cells with a T cell phenotype (T-LAK) sensitized with two kinds of bsAbs to human BDC-grafted severe combined immunodeficient (SCID) mice demonstrated remarkable inhibition of tumor growth. However, complete cures could not be obtained. In order to improve antitumor efficacy, we have paid attention to anti-CD2 monoclonal antibodies (mAbs), thought to play an important roles in signal transduction in T cell activation or control of T cell receptor (TCR)-driven activation. Therefore, we developed another bsAb, anti-MUC1 × anti-CD2 (M × 2), in order to examine if this would show synergism with the two previously described bsAbs. The combination of the three bsAbs (M × 3, M × 28 and M × 2 bsAbs) showed highest cytotoxicity against MUC1-expressing BDC cells when given simultaneously with peripheral blood mononuclear cells (PBMCs) or T-LAK cells in vitro. When 2 × 107 T-LAK cells sensitized with different combinations of bsAbs were administered four times i.v. to BDC-grafted SCID mice, the best therapeutic result was obtained with a combination of all three bsAbs. These results indicate usefulness of combination of three bsAbs for targeting cancer immunotherapy.

Original languageEnglish
Pages (from-to)99-106
Number of pages8
JournalImmunology Letters
Issue number2
Publication statusPublished - 2002 Apr 22


  • Bispecific antibodies
  • Immunotherapy
  • MUC1
  • T-LAK

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies'. Together they form a unique fingerprint.

Cite this